Irish biotech Aerska raises €32M to deliver RNA medicines to the brain, targeting Alzheimer’s and Parkinson’s at their genetic roots.

TNW is a technology media company that covers the latest trends, news, and insights in the tech industry. With a focus on innovation, entrepreneurship, and digital culture, TNW offers resources for developers, startups, and tech enthusiasts. Developers can learn about emerging technologies, industry trends, and best practices through TNW's articles, podcasts, and events.

The Next Web

Irish biotech startup Aerska secured $39M in funding to develop technology that delivers RNA-based medicines across the blood-brain barrier. The company aims to treat neurodegenerative diseases like Alzheimer's and Parkinson's by targeting disease-causing proteins at their genetic source, rather than just managing symptoms. The funding, co-led by EQT Life Sciences and age1, will support preclinical development and early clinical trials of their systemic RNA delivery platform.

Aerska raises $39M to help RNA medicines reach the brain